Péter Ferdinandy and Zsuzsanna Helyes, President and Secretary General of the Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR), share their insights about the role of the society, the R&D capabilities of the Hungarian pharmaceutical industry, the ability of local players to bring innovations to the market, and the future strategic direction of HUPHAR.
This year we awarded Novartis for their drug called Entresto in cardiology and Janssen-Cilag for Imbruvica in haemato-oncology.
